Cancer Metabolism

Innovating through Metabolic Science and by Empowering Immunity.

Cornerstone addresses significant unmet needs with therapies for hard-to-treat cancers

Cancer Metabolism Therapy with Cornerstone Pharmaceuticals

Passion. Hope. Performance.

Developing innovative cancer therapies that will transform the way we treat patients.

Development of drugs that targets the metabolic foundation for tumor growth and simultaneously harness the immune system in hard-to-treat cancers with significant medical unmet needs.

With science stemming from the world’s most renowned institutions and compassion that runs deep, Cornerstone strives to improve the lives of people with hard-to-treat cancers, inaugurating a new era of hope.

CPI-613® (devimistat)

Cornerstone’s lead compound, CPI-613® (devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth.

Devimistat is undergoing multiple clinical trials and has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the following indications: Burkitt’s lymphoma, biliary tract cancer, soft tissue sarcoma, myelodysplastic syndrome (MDS) and peripheral T-cell lymphoma. In addition, the European Medicines Agency (EMA) has granted orphan drug designation to devimistat for Burkitt’s lymphoma.

Learn More

World Class Team

Innovation in oncology drug development requires a deep well of scientific, medical and business expertise, and we have assembled an unparalleled team of directors and advisors who are working with Cornerstone to revolutionize anticancer treatment.

Our Board of Directors and Scientific & Medical Advisory Boards are drawn from the highest echelons of oncology and hematology researchers and physicians, and include seasoned managers from the biotech and pharmaceutical sectors.